Combination comprising an HMG-CoA reductase inhibitor and an insulin secretor enhancer or an insulin senstizer

摘要

Disclosed is a combination, especially a pharmaceutical composition, consisting of: (i) a HMG CoA reductase inhibitor selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simuvastatin and (ii) pyrrolidine, 1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-, (S) useful in the treatment of hyperlipidaemia, dyslipidaemia, diabetes mellitus type 2 and obesity.